Replies to post #140283 on Biotech Values

[bladerunner1717]

Hey McBio,

A couple of notes on the ECYT CC, which I actually thought was rather lame. None of the really interesting questions around milestones, royalties or standstill agreements (I'm not exactly sure what they are.) got answered.

A few notes on things that weren't in the PR: The Phase III trial, the PROCEED trial, will cost about $40 million, most or all of the cost to be borne by ECYT.

The Phase II in lung cancer will enroll about 180 patients and cost about $15 million. Cost to be all borne by MRK, but be run by ECYT.

No SPA with the FDA for the Phase III here in U.S. CEO reminded the questioner that the FDA will not grant an SPA in ovarian where OS is not the primary endpoint. This confirms, a bit obliquely, that the Phase III in the U.S. will have PFS as the primary endpoint, which is what my sources had told me.

ECYT management made a really huge deal out of the fact that they had retained all rights to EC20, the diagnostic test they have for the folate marker. They must have mentioned this about ten times. No kidding. (I don't think jq1234 or anyone here has talked much about the value of the diagnostic test, but management seems to think that it's a big deal.) There will be a joint committee between MRK and ECYT to work out the details of how the test will be used in the new trials and in the other cancer indications that MRK wants to test EC145 in.

ECYT's next three new drugs in development will target inflammatory diseases and one will be a ADC for prostate cancer.

As you all know, I'm not knowledgeable in these areas, but I try to understand the best I can with my feeble medical/scientific brain, so feel free to correct, amend or criticize what my understandings are here.

And a special thanks to McBio for reinforcing my early thoughts about the company after the alleged "failed" Phase II. I actually did double down and sorry to hear that you didn't, but glad you made out great with what you had. And thanks to jq1234 for his always insightful comments. Like McBio, I'm not selling anything yet.


Bladerunner